Fate therapeutics inc (FATE)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Collaboration revenue

10,680

4,740

4,106

4,402

2,431

-

626

1,268

833

Grant revenue

-

-

-

-

-

-

345

1,402

337

Total revenue

-

-

-

-

-

-

971

2,670

1,170

Operating expenses:
Research and development

87,770

56,024

34,358

26,452

19,861

16,435

12,007

11,999

9,858

General and administrative

23,637

15,808

11,873

9,913

10,352

8,469

6,639

4,228

4,605

Total operating expenses

111,407

71,832

46,231

36,365

30,213

24,904

18,646

16,227

14,463

Loss from operations

-100,727

-67,092

-42,125

-31,963

-27,782

-24,904

-17,675

-13,557

-13,293

Other income (expense):
Interest income

4,330

2,190

559

138

10

2

6

1

2

Interest expense

1,752

1,696

1,268

1,637

2,220

549

796

487

127

Loss on extinguishment of debt

-

-

-118

-

-

-432

-

-323

-9

Change in fair value of exchangeable shares

-

-

-

-

-

-

-2,421

-90

5

Change in fair value of warrant liability

-

-

-

-

-

-

8

-37

-5

Total other income, net

2,578

494

-827

-1,499

-2,210

-979

-3,219

-682

-134

Net loss

-98,149

-66,598

-42,952

-33,462

-29,992

-25,883

-20,894

-14,239

-13,427

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities, net

24

1

-2

-1

-

-

-

-

-

Comprehensive loss

-98,125

-66,597

-42,954

-33,463

-29,992

-25,883

-

-

-

Net loss per common share, basic and diluted

-1.44

-1.19

-1.02

-1.05

-1.18

-1.27

-3.54

-13.06

-16.16

Weighted-average common shares used to compute basic and diluted net loss per share

68,190

56,195

41,982

31,754

25,484

20,451

5,896

1,090

830